CSL wins FDA approval for blockbuster drug
Chief executive Paul Perreault says the FDA’s approval for the company’s new drug Hemgenix – the world’s first gene therapy treatment for haemophilia – is ‘historic’.
Csl
Four healthcare stocks ready to rebound
Healthcare leaders struggled during the pandemic, but it’s time to look again at some of the better players.
Last Post: COP27, Bowen, nuclear and Stuff the British Gave Us
Why are climate change conferences invariably held in glamorous resorts, not in impoverished, energy-poor places where the push for renewables is meaningless?
CSL sets sights on Covid-19, influenza ‘superjab’
Combining vaccines for Covid-19 and influenza into a single shot is edging closer to reality thanks to self-amplifying messenger RNA technology, and CSL is getting in on the action.
ASX closes up; Medibank stocks among top risers
Local stocks end the day higher led by materials and energy gains. CBA hikes home loan, savings rates. Loan values fell in September. Rio lifts after winning over Turquoise investors. Inflation boost for Amcor. AGL up as Cannon-Brookes wins backing in board battle.
How CSL plans to make Vifor the jewel in its crown
Paul Perreault says Vifor Pharma, which it bought for $16.4bn this year, has huge opportunities as a global leader in the treatment of iron deficiency.
CSL opts for investment over split, buyback
CSL’s board is aware of investor interest in share buybacks and splitting but will invest in its business and pursue further acquisitions.
CSL’s plan to combat Russian energy freeze
Australia’s biggest health company, CSL, has robust strategies to protect its European plants against the threat of rolling blackouts.
Powering ahead on net zero leads only to a world of pain
As the world wakes up to the fact the climate policy goal of achieving net-zero CO2 emissions brings crippling economic pain, emerging economies are baulking at emulating the rich.
ASX drops 1.6pc; coal miners lead energy wipeout
ASX hits a three-month low as energy and miners plunge. Dollar hits 29-month low, New Hope leads coal losses, Costa smashed on CEO exit and health stock rally.
Nation’s biggest health companies vow to cut carbon footprint
Australia’s biggest health companies are launching a range of strategies to cut carbon emissions, saying environmental goals are “inextricably linked” to healthcare.
CSL blindsided by Morrison becoming health minister
The pharmaceutical company says it had no idea it had to deal with two health ministers when it was tasked with producing the majority of Australia’s Covid-19 vaccine supply.
ASX in black, Challenger, Super Retail up
ASX ends 0.3 per cent higher, recording its best close in 10 weeks. Investors pile into Challenger, BHP, Wesfarmers, Brambles and Super Retail with a flurry of earnings results. CSL lost ground after profit fell.
ASX extends gains; BHP soars, Challenger dives
ASX exits technical correction as BHP lifts on profit beat. Challenger smashed on results; Seek falls after reporting, Life360 jumps on outlook and consumer confidence rebounds.
CSL gets its mojo back
CSL’s $16.4bn acquisition of Swiss biotech Vifor Pharma gets a thumbs up from a faithful shareholder base.
ASX extends winning streak after RBA hike
ASX rises for a sixth straight day after the RBA’s 50bps hike. Zip and A2 Milk surge, Appen dives on update, Telstra completes Fetch acquisition and United Malt selloff extends.
Covid-19: Heed lessons ‘or risk a monkeypox disaster’
An outbreak of monkeypox has created a barometer on how much the world has learned from Covid-19 and how to better fund biotech companies.
100-day target for new Covid-19 vaccines
Researchers are under mounting pressure to deliver with the development of new vaccines now slashed to 100 days after first Covid-19 shot took a year.
Climate diplomacy underlines defence gap
Taking action on climate change is seen by the government as a strategy to meet the emerging China threat in the Pacific. But its first duty is to secure the nation’s defence.
ASX falls; BHP, Fortescue, Rio hit 8-month lows
Fresh recession jitters sends ASX lower as materials and energy plunge. Megaport and Zip surge, St Barbara falls sharply, CSL hits six-month high and Bitcoin below $US20,000.
No shame in changing our mind about the elephant in the room
No one seriously believes solar and wind alone will propel us to a 43 per cent reduction in CO2 emissions by 2030 — but the facts on nuclear power have altered significantly in the past two decades.
ASX adds 0.3pc; CSL, Goodman, Blackmores lifts
ASX rebounds led by real estate and health. Lake Resources crashes as it calms investors, NBN taps bond market, Growthpoint jumps on forecast and PayGroup’s stunning surge.
Small nuclear reactors would get us to carbon neutral
If the anti-nukers hadn’t interfered, Australia would have a clean, green energy source by now – and we’d be a richer nation for it.
ASX flat; CSL, NAB, ANZ lead declines
ASX trims gains as a China Covid surge spooks traders. Geoff Wilson against AGL demerger, Codan up on profit beat, Incitec slips on demerger plans and outgoing Star chair gives evidence.
ASX jumps 1.9pc; tech, health care drive gains
ASX posts its third best session for 2022 as tech stocks lead charge. Block jumps 15 per cent as IGO lags, BGH extends Virtus offer, Star director to quit and bitcoin leaps.
ASX rises in volatile trade; CSL leads gains
ASX ends three-day losing streak ahead of US inflation numbers. CSL leads health care rally, Link plunges amid takeover jitters, Magellan lifts on CEO and job ads hit fresh high.
Lack of staff a ‘limiting factor’: CSL
The biotech giant has deferred a marketing campaign for donors to push plasma volumes higher until new employees get trained after moves to stem existing staff attrition.
CSL diagnosis could get better from here
Australia’s biggest stock (which is not a miner or a bank) is down but by no means out.
CSL’s share price set for $400, Morgan Stanley says
A Swiss renal treatments company could elevate CSL to reclaim its spot as the biggest company on the ASX.
ASX ends flat; Ramsay soars
ASX 200 gives up gains to finish steady. Ramsay Health rallies on $20bn KKR bid. CSL, Wesfarmers and Whitehaven also strong. Rio Tinto drops after poor quarter.
Original URL: https://www.theaustralian.com.au/topics/csl/page/4